Based on the promising results of CodeBreak 100, sotorasib received accelerated approval from the FDA in May 2021 for patients with KRAS-G12C-mutated NSCLC who had been treated with at least one prior line of anticancer therapy [56]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.